26
|
Song YW, Yu HM, Park KS, Lee JM. A CASE OF SPONTANEOUS REGRESSION OF IDIOPATHIC BILATERAL ADRENAL HEMORRHAGE IN A MIDDLE AGED WOMAN: 1 YEAR FOLLOW-UP. ACTA ENDOCRINOLOGICA-BUCHAREST 2016; 12:85-90. [PMID: 31258807 DOI: 10.4183/aeb.2016.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Background Bilateral adrenal hemorrhage is a serious condition that can result in adrenal insufficiency, shock, acute adrenal crisis, and mortality if it is not managed with adequate treatment. We report a rare case of idiopathic bilateral adrenal hemorrhage. Case presentation A 50-year-old woman visited our hospital with complaints of right upper abdominal pain. A computed tomography (CT) revealed unilateral left adrenal gland hemorrhage. However, the results of rapid adrenocorticotropic hormone (ACTH) stimulation test and adrenomedullary hormone function test were normal. Since the patient did not show signs of adrenal insufficiency, corticosteroid therapy was postponed and only supportive management therapy was started. After 1 week, a follow- up CT showed a previously unseen adrenal hemorrhage on the right adrenal gland, but the rapid ACTH stimulation test result was normal. One year later, no hemorrhagic signs were observed on the follow-up CT. Conclusion In most cases of idiopathic bilateral adrenal hemorrhage, patients are treated with steroid replacement therapy due to adrenal insufficiency. In some other cases, patients are treated with steroids despite the absence of adrenal insufficiency. Here we reported a very rare case of idiopathic bilateral adrenal hemorrhage sequentially to emphasize that before initiation of adrenal hormone replacement therapy, it is important to determine whether adrenal insufficiency is present. If there is no evidence of adrenal insufficiency, adrenal replacement therapy should be postponed until the presence of adrenal insufficiency is confirmed.
Collapse
|
27
|
Moon JH, Moon JH, Kim KM, Choi SH, Lim S, Park KS, Kim KW, Jang HC. Sarcopenia as a Predictor of Future Cognitive Impairment in Older Adults. J Nutr Health Aging 2016; 20:496-502. [PMID: 27102786 DOI: 10.1007/s12603-015-0613-x] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
OBJECTIVES We investigated the association between the indices of sarcopenia and future risk of cognitive impairment in older adults. DESIGN Community-based prospective cohort study. SETTING Community. PARTICIPANTS A total of 297 participants aged ≥65 years without cognitive impairment at baseline (mean age, 71.9 ± 6.6 years; men:women, 158:139) and who underwent cognitive evaluation at the 5-year follow-up. MEASUREMENTS Sarcopenia parameters including appendicular lean mass (ALM), handgrip strength, and the Short Physical Performance Battery (SPPB) score at baseline were compared according to the later progression of mild cognitive impairment (MCI) and/or dementia. The operational criteria suggested by the Foundation for the National Institutes of Health Sarcopenia Project were used. We performed multivariate logistic regression analysis to identify the independent indicators of the progression of cognitive impairment. RESULTS Among the 297 participants, 242 (81.5%) remained cognitively normal (nonprogression group), whereas 55 (18.5%) showed progression of cognitive impairment (50 subjects (16.8%) to MCI and 5 subjects (1.7%) to dementia) (progression group). Compared with the nonprogression group, subjects in the progression group were older, had a lower educational level, and had lower physical function as assessed by the SPPB; a higher percentage were depressed. Other baseline markers of sarcopenia, including the ALM-to-body mass index ratio and handgrip strength did not differ significantly between the groups. The association between a low SPPB score (<9) and progression of cognitive impairment was maintained after adjustment for conventional risk factors for cognitive impairment (hazard ratio 2.222, 95% confidence interval 1.047-4.716, P = 0.038). CONCLUSION Decreased physical performance, as assessed by the SPPB, but not other markers of sarcopenia, was independently associated with the risk of later cognitive impairment in older adults.
Collapse
|
28
|
Jin SM, Park SW, Yoon KH, Min KW, Song KH, Park KS, Park JY, Park IB, Chung CH, Baik SH, Choi SH, Lee HW, Lee IK, Kim DM, Lee MK. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab 2015; 17:511-5. [PMID: 25523633 DOI: 10.1111/dom.12429] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Revised: 12/06/2014] [Accepted: 12/15/2014] [Indexed: 12/20/2022]
Abstract
We conducted a 24-week, multicentre, double-blind, randomized study with a 28-week extension to compare the efficacy and safety of anagliptin and sitagliptin as an add-on to metformin in patients with type 2 diabetes. Patients inadequately controlled on metformin were randomized to either anagliptin (100 mg twice daily, n = 92) or sitagliptin (100 mg once daily, n = 88). The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline to week 24. The mean changes in HbA1c were -0.85 ± 0.70% (p < 0.0001) for anagliptin and -0.83 ± 0.61% (p < 0.0001) for sitagliptin, with a mean difference of -0.02% (95% confidence interval of difference, -0.22 to 0.18%). In both groups, the fasting proinsulin : insulin ratio significantly decreased from baseline, with improved insulin secretion. Safety profiles were similar in each group. In conclusion, the non-inferiority of the efficacy of anagliptin to sitagliptin as an add-on therapy was established with regard to efficacy and safety.
Collapse
|
29
|
Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil 2015; 27:705-16. [PMID: 25809913 DOI: 10.1111/nmo.12544] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Accepted: 02/17/2015] [Indexed: 12/11/2022]
Abstract
BACKGROUND Probiotics can be beneficial in irritable bowel syndrome (IBS). Mosapride citrate, a selective 5-HT4 receptor agonist, stimulates gastrointestinal motility. We investigated the efficacy of combination therapy with probiotics and mosapride for non-diarrheal-type IBS. METHODS Two hundred and eighty-five IBS patients were randomly assigned to either a combination of probiotics (Bacillus subtilis and Streptococcus faecium) and mosapride at one of four different doses or a placebo for 4 weeks. The primary outcome was the proportion of patients experiencing adequate relief (AR) of global IBS symptoms at week 4. The secondary outcomes included subject's global assessment (SGA) of IBS symptom relief, individual symptoms, stool parameters, and IBS-quality of life. KEY RESULTS The proportion of AR at week 4 was significantly higher in all treatment groups compared to the placebo group (53.7% in group 1, 55.0% in group 2, 55.2% in group 3, 53.6% in group 4 [the highest dose], and 35.1% in placebo group, respectively, p < 0.05). The proportion of patients reporting 'completely or considerably relieved' in the SGA was higher in the treatment groups than in the placebo group. The abdominal pain/discomfort score in the treatment group 4 was more prominently improved compared with that of the placebo group. In patients with constipation-predominant IBS, the improvements in stool frequency and consistency were significantly higher in the treatment groups 4 and 1, respectively, than those in the placebo group. CONCLUSIONS & INFERENCES Combination therapy with probiotics and mosapride is effective for relief of symptoms in patients with non-diarrheal-type IBS. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT01505777).
Collapse
|
30
|
Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ, Chung CH, Kim KA, Lee HW, Park IB, Park JY, Chul Jang HC, Park KS, Jang WI, Cha BY. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab 2015; 17:309-12. [PMID: 25475929 PMCID: PMC6680285 DOI: 10.1111/dom.12424] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2014] [Revised: 11/28/2014] [Accepted: 12/01/2014] [Indexed: 12/01/2022]
Abstract
The aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in Korean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy. Patients [glycated haemoglobin (HbA1c) 7.0-10.0%, on stable metformin ≥1000 mg/day] were randomized 2 : 1 to receive 20 mg teneligliptin plus metformin (n = 136) or placebo plus metformin (n = 68). The primary endpoint was the change in HbA1c levels from baseline to week 16. The mean baseline HbA1c was 7.9% in the teneligliptin group and 7.8% in the placebo group. The differences between the teneligliptin and placebo groups regarding changes in HbA1c and fasting plasma glucose levels were -0.78 % and -1.24 mmol/l (22.42 mg/dl), respectively, at week 16. The incidence of adverse events was similar between the groups. The addition of teneligliptin once daily to metformin was effective and generally well tolerated in Korean patients with type 2 diabetes.
Collapse
|
31
|
Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16:900-9. [PMID: 24655583 DOI: 10.1111/dom.12293] [Citation(s) in RCA: 121] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2013] [Revised: 02/14/2014] [Accepted: 03/16/2014] [Indexed: 12/27/2022]
Abstract
AIMS To compare the HbA1c-lowering efficacy of glucagon-like peptide-1 (GLP-1) analogues between Asians and non-Asians with type 2 diabetes. METHODS We searched randomized controlled trials from MEDLINE, EMBASE, LILACS, CENTRAL and ClinicalTrials.gov. Studies described in English were included if the treatment duration was 12 weeks or more, information about ethnicity and baseline HbA1c values were available and a GLP-1 analogue was compared with a placebo. For the ethnic comparison, we divided the studies into Asian-dominant studies (≥ 50% Asian participants) and non-Asian-dominant studies (<50% Asian participants). RESULTS Among the 837 searched studies, 15 trials were included for the meta-analysis. The weighted mean difference of HbA1c with GLP-1 analogues was -1.16% [95% confidence interval (CI) -1.48, -0.85] in the Asian-dominant studies and -0.83% (95% CI -0.97, -0.70) in the non-Asian-dominant studies. The between-group difference was -0.32% (95% CI -0.64, -0.01; p = 0.04). The relative risk (RR) with 95% CIs for achieving the target HbA1c ≤ 7.0% tended to be greater in the Asian-dominant studies [RR 5.7 (3.8, 8.7)] than in the non-Asian-dominant studies [RR 2.8 (2.4, 3.3)]. Body weight changes were similar between the two groups. Hypoglycaemia tended to be more common in Asian-dominant studies (RR 2.8 [2.3, 3.5]) than in non-Asian-dominant studies (RR 1.5 [1.2, 1.8]), but severe hypoglycaemia was very rare in both groups. CONCLUSION GLP-1 analogues lower HbA1c more in Asian-dominant studies than in non-Asian-dominant studies. Further studies are warranted to explore the potential mechanisms of the ethnic difference.
Collapse
|
32
|
Park SR, Park KS, Park YJ, Bang D, Lee ES. CD11a, CD11c, and CD18 gene polymorphisms and susceptibility to Behçet's disease in Koreans. ACTA ACUST UNITED AC 2014; 84:398-404. [PMID: 25155097 DOI: 10.1111/tan.12420] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Revised: 05/04/2014] [Accepted: 07/14/2014] [Indexed: 11/29/2022]
Abstract
Lesions of Behçet's disease (BD) show vascular infiltrates of immune cells expressing integrins. β2 integrins (CD11/CD18) play a major role in cell migration to the inflammatory lesion and also induce cytokine production. Thus, genetic polymorphisms of CD11/CD18 may be associated with the pathogenesis of BD. In this study, nine single nucleotide polymorphisms (SNPs) of the CD11a, CD11c, and CD18 were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and haplotype analysis in 305 BD patients and 266 healthy controls. The frequencies of genotype rs11574944 CC and haplotype rs11574944C-rs2230433G-rs8058823A in CD11a were significantly lower in BD patients. The frequencies of genotype rs2230429 CC, rs2929 GG, and haplotype rs2230429C-rs2929G in CD11c were higher in BD patients. The frequencies of genotype rs235326CC and haplotype rs2070946A-rs235326C-rs760456G-rs684G in CD18 were significantly higher in the BD patients than in the controls. Other SNPs in CD11a, CD11c, and CD18 gene were not significantly different. Therefore, the major genotype and haplotype of CD11a/CD18 may play a role in decreasing the susceptibility of BD, whereas the major genotype and haplotype of CD11c/CD18 may play a role in increasing the susceptibility of BD.
Collapse
|
33
|
Abstract
AbstractApplying newly devised model, heritability (VA/VP) of plasma uric acid level, corrected for age and sex and standardized, was estimated at 0.8 in families consisting of twin parents, spouses and children. Correlation between spouses due to common genotype (ρ) was approximately 0.1, and variance due to common familial environment (VEC/Vp) was -0.3. Analysis of families of selected twin children and their parents resulted in two estimates of heritability: approximately 0.7 and 0.3, ρ being 0.34 and 0.04, and VEC/Vp being 0.04 and 0.34, respectively. Regression of IQ (y) on corrected and standardized plasma uric acid level (x) in the twin children was y = 5.56x + 123, correlation being 0.334 (p < 0.025). The result indicates a genetic basis of blood uric acid level, which may have resulted from polymorphisms in purine metabolism pathway, end product of which is uric acid in man. The significant correlation between plasma uric acid level and IQ suggests a contribution of partly common gene loci to the two quantitative traits.
Collapse
|
34
|
Park HJ, Jeong GC, Kwon SY, Min JJ, Bom HS, Park KS, Cho SG, Kang SR, Kim J, Song HC, Chong A, Yoo SW. Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma. Nucl Med Mol Imaging 2014; 48:255-61. [PMID: 26396629 DOI: 10.1007/s13139-014-0282-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Revised: 05/19/2014] [Accepted: 05/22/2014] [Indexed: 11/30/2022] Open
Abstract
PURPOSE To investigate the clinical importance of serum thyroglobulin (Tg) levels just before high-dose I-131 ablation therapy (preablation Tg) for predicting therapeutic failure in patients with papillary thyroid carcinoma (PTC). METHODS Patients with PTC (n = 132) undergoing total thyroidectomy followed by the first high-dose I-131 ablation therapy (HI-Rx) were included in this retrospective review. Just before HI-Rx, preablation Tg, anti-Tg antibody, and TSH were measured. The patients were followed up for a mean period of 7 months (range 6-23 months) by I-123 whole-body scans (f/u IWBS) and stimulated Tg (f/u Tg). Therapeutic failure was defined by positive f/u IWBS or f/u Tg >2 ng/ml. We classified patients into three groups according to the value of preablation Tg (group 1, <1 ng/ml; group 2, ≥1 and <10 ng/ml; group 3, ≥10 ng/ml) and compared clinical variables to therapeutic response. RESULTS Therapeutic failure was noted in 39 patients (29.5 %). On univariate analysis, T stage, tumor size, and preablation Tg were the statistically significant factors that could predict therapeutic failure. After multivariate analysis, preablation Tg was the only independent predictor of therapeutic failure (P < 0.001). The therapeutic failure rate was significantly increased as the preablation Tg level increased (11.3 %, 33.3 %, and 87.5 % in groups 1, 2, and 3, respectively; P < 0.001). Individuals with preablation Tg levels ≥10 ng/ml had 25.5 times greater chance of therapeutic failure than those with levels <10 ng/ml (95 % CI = 5.43-119.60; P < 0.001). CONCLUSIONS A high preablation Tg level is the most significant predictor of therapeutic failure at the time of first HI-Rx in patients with PTC.
Collapse
|
35
|
Kim DW, Woo HD, Joo J, Park KS, Oh SY, Kwon HJ, Park JD, Hong YS, Sohn SJ, Yoon HJ, Hwang MS, Kim J. Estimated long-term dietary exposure to lead, cadmium, and mercury in young Korean children. Eur J Clin Nutr 2014; 68:1322-6. [PMID: 24961543 DOI: 10.1038/ejcn.2014.116] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Revised: 03/10/2014] [Accepted: 04/13/2014] [Indexed: 11/09/2022]
Abstract
BACKGROUND Controlling for day-to-day variation is a key issue in estimating long-term dietary exposure to heavy metals using 24-hour recall (24HR) data from a relatively small number of days. OBJECTIVES This study was conducted to estimate long-term dietary exposure to lead, cadmium and mercury among Korean children using the Iowa State University (ISU) method and to assess the contributions of different food groups to heavy metal intake. METHODS We analyzed 2 days of 24HR data from 457 children between 0 and 6 years of age in 2010. Using bootstrapped concentration data for 118 representative foods, 93.5% of total intake was included in the exposure estimates in this study. Using the 2-day exposure data, we estimated long-term exposure by controlling for within-individual variation using the ISU method. RESULTS The long-term dietary exposure estimates (mean±standard deviation) for lead, cadmium, and mercury were 0.47±0.14, 0.38±0.20, and 0.22±0.08 μg/kg bw/day, respectively. For lead and cadmium, the percentages of children whose exposure was greater than the reference value were 35 and 42%, respectively. Fruits were an important source of lead exposure, and cereal and fish and shellfish made the greatest contributions to the total cadmium and mercury exposure. CONCLUSIONS Our findings also suggest that the long-term exposure to lead and cadmium was somewhat greater than the reference values, whereas mercury exposure was well below than the reference value in this population. Further studies may be necessary to evaluate the food items contributing to heavy metal exposure, and continuous monitoring is needed to ensure the safety of food intake and dietary patterns among vulnerable groups in Korea.
Collapse
|
36
|
Sim SY, Lee WK, Baek HJ, Park KS. A nonintrusive temperature measuring system for estimating deep body temperature in bed. ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE 2013; 2012:3460-3. [PMID: 23366671 DOI: 10.1109/embc.2012.6346710] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Deep body temperature is an important indicator that reflects human being's overall physiological states. Existing deep body temperature monitoring systems are too invasive to apply to awake patients for a long time. Therefore, we proposed a nonintrusive deep body temperature measuring system. To estimate deep body temperature nonintrusively, a dual-heat-flux probe and double-sensor probes were embedded in a neck pillow. When a patient uses the neck pillow to rest, the deep body temperature can be assessed using one of the thermometer probes embedded in the neck pillow. We could estimate deep body temperature in 3 different sleep positions. Also, to reduce the initial response time of dual-heat-flux thermometer which measures body temperature in supine position, we employed the curve-fitting method to one subject. And thereby, we could obtain the deep body temperature in a minute. This result shows the possibility that the system can be used as practical temperature monitoring system with appropriate curve-fitting model. In the next study, we would try to establish a general fitting model that can be applied to all of the subjects. In addition, we are planning to extract meaningful health information such as sleep structure analysis from deep body temperature data which are acquired from this system.
Collapse
|
37
|
Lee HY, Kim ES, Lee YJ, Ha YJ, Cho KB, Park KS. Fatal outcome following gastric endoscopic submucosal dissection in a patient with liver cirrhosis. Endoscopy 2013; 44 Suppl 2 UCTN:E431-2. [PMID: 23258489 DOI: 10.1055/s-0032-1325858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
|
38
|
Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56:696-708. [PMID: 23344728 DOI: 10.1007/s00125-012-2827-3] [Citation(s) in RCA: 301] [Impact Index Per Article: 27.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2012] [Accepted: 12/19/2012] [Indexed: 12/25/2022]
Abstract
AIMS/HYPOTHESIS The aim of this work was to compare the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors between Asian and non-Asian patients with type 2 diabetes. METHODS We searched MEDLINE, EMBASE, LILACS, CENTRAL, ClinicalTrials.gov and conference proceedings. Studies were eligible if they were randomised controlled trials with a treatment duration of at least 12 weeks, compared a DPP-4 inhibitor with a placebo as either monotherapy or oral combination therapy, had information on ethnicity and HbA1c values and were published or described in English. A systematic review and meta-analysis with a meta-regression analysis was conducted. RESULTS Among 809 potentially relevant studies, 55 trials were included. A meta-analysis revealed that DPP-4 inhibitors lowered HbA1c to a greater extent in studies with ≥50% Asian participants (weighted mean difference [WMD] -0.92%; 95% CI -1.03, -0.82) than in studies with <50% Asian participants (WMD -0.65%; 95% CI -0.69, -0.60). The between-group difference was -0.26% (95% CI -0.36, -0.17, p < 0.001). The baseline BMI significantly correlated with the HbA1c-lowering efficacy of DPP-4 inhibitors. The RR of achieving the goal of HbA1c <7.0% (53.0 mmol/mol) was higher in studies with ≥50% Asian participants (3.4 [95% CI 2.6, 4.7] vs 1.9 [95% CI 1.8, 2.0]). The fasting plasma glucose-lowering efficacy was higher with monotherapy in the Asian-dominant studies, but the postprandial glucose-lowering efficacy and changes in body weight were comparable between the two groups. CONCLUSIONS/INTERPRETATION DPP-4 inhibitors exhibit a better glucose-lowering efficacy in Asians than in other ethnic groups; this requires further investigation to understand the underlying mechanism, particularly in relation to BMI.
Collapse
|
39
|
Hwang YC, Kang M, Ahn CW, Park JS, Baik SH, Chung DJ, Jang HC, Kim KA, Lee IK, Min KW, Nam M, Park TS, Son SM, Sung YA, Woo JT, Park KS, Lee MK. Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes. Int J Clin Pract 2013; 67:236-43. [PMID: 23336668 DOI: 10.1111/ijcp.12071] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
AIMS The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM-SR) 2/500 mg, a fixed-dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed-dose combination, twice daily in patients with type 2 diabetes (T2D). METHODS A multicentre, randomised, double-blind, double-dummy study was conducted in 14 hospitals in Korea. Inclusion criteria were age 30-75 years, T2D diagnosis no longer than 10 years previously, A1C between 7% and 10%, and body mass index <40 kg/m(2) . A total of 207 subjects were randomised into the GM-SR group (n=101) or the GM group (n=106). Participants were assessed at baseline, 8 weeks and 16 weeks after treatment. RESULTS After 16 weeks treatment, no difference in baseline-adjusted changes of A1C (primary efficacy variable) was observed between the two groups (-0.59% for GM-SR group vs. -0.61% for GM group, 95% CI: -0.17 to 0.21; p=0.84). In addition, there were no significant differences in secondary efficacy parameters between the two groups, including changes in A1C up to week 8, changes in fasting plasma glucose (FPG) and 2-h-postprandial plasma glucose up to week 8 and week 16, response rate, drug compliance and hypoglycaemic events. However, there was a difference in baseline-adjusted changes of FPG between the two groups (-1.01 mmol/l for GM-SR group vs. -1.52 mmol/l for GM group, p=0.01 in the intention to treat set). CONCLUSIONS GM-SR 2/500 mg once daily was as effective as GM 1/250 mg twice daily in lowering A1C. In addition, no difference was noted in hypoglycaemic events between the two groups.
Collapse
|
40
|
Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012; 14:795-802. [PMID: 22443183 DOI: 10.1111/j.1463-1326.2012.01600.x] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
AIM Individuals requiring insulin therapy for type 2 diabetes often require escalation of their regimen to achieve glycaemic control. Optimal management strategies for uncontrolled type 2 diabetes would improve glycaemic control without hypoglycaemia and weight gain. This study compared the efficacy and tolerability of adding sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, and an up to 20% increase in insulin dose in patients with uncontrolled type 2 diabetes on insulin therapy. METHODS We conducted a 24-week, randomized, active-competitor, parallel-group study in subjects with uncontrolled type 2 diabetes [haemoglobin A1c (HbA1c) = 7.5-11%] currently using insulin therapy. Subjects were randomly assigned to either the sitagliptin adding (100 mg daily, n = 70) or an insulin-increasing arm (≥ 10% at week 12 and ≥ 10% at week 24, n = 70) while continuing other medications. RESULTS Average baseline HbA1c was 9.2% in both groups. HbA1c decreased more at 24 weeks in the sitagliptin adding than the insulin-increasing arm (-0.6 ± 0.1% vs. -0.2 ± 0.1%, p < 0.01). Insulin was increased by 25% at 24 weeks in the insulin-increasing group. Hypoglycaemic events were less common and less severe in sitagliptin adding arm than insulin-increasing arm (7.0 vs. 14.3 events per patient-year, p < 0.05). Weight was stable in the sitagliptin adding subjects (68.6 ± 11.6 vs. 68.1 ± 11.4 kg) but increased in the insulin-increasing subjects (66.2 ± 10.6 vs. 67.4 ± 9.7 kg, p < 0.05). Other adverse events occurred at similar rates in both arms. CONCLUSIONS Compared to a 25% increase in insulin dose, adding sitagliptin to an insulin-based regimen was more effective at lowering HbA1c and associated with less hypoglycaemia and weight gain over 24 weeks. CLINICAL TRIAL NUMBER NCT01100125.
Collapse
|
41
|
Sohn W, Lee OY, Kwon JG, Park KS, Lim YJ, Kim TH, Jung SW, Kim JI. Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study. Neurogastroenterol Motil 2012; 24:860-e398. [PMID: 22679908 DOI: 10.1111/j.1365-2982.2012.01945.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Tricyclic antidepressants have good efficacy in irritable bowel syndrome with diarrhea (IBS-D), but their clinical use is limited by considerations of tolerability. Tianeptine, another antidepressant, acts as a selective serotonin reuptake enhancer. We compared tianeptine with amitriptyline for the treatment of patients with IBS-D. METHODS We undertook a multicenter, randomized, open-label, non-inferiority clinical study that compared tianeptine with amitriptyline, each in combination with probiotics, for the treatment of IBS-D. Subjects were randomized to receive tianeptine (37.5 mg)/probiotics (Bacillus subtilis + Streptococcus faecium) or amitriptyline (10 mg)/probiotics (Bacillus subtilis + Streptococcus faecium) for 4 weeks. A total of 228 patients were analyzed by the intention-to-treat approach. The primary efficacy endpoint was the proportion of patients who had global relief of IBS symptoms at week 4. The secondary efficacy endpoints were intensity of abdominal pain/discomfort, stool frequency/consistency, quality of life, and overall satisfaction with treatment. KEY RESULTS At week 4, non-inferiority of the tianeptine group to the amitriptyline group (treatment difference -15.1%; 95% CI -26.6% to -3.8%) was shown, with 81.1% (99 of 122 patients) of the patients in the tianeptine group and 66.0% (70 of 106 patients) in the amitriptyline group reporting global relief of IBS symptoms. The secondary endpoints also demonstrated non-inferiority of the tianeptine group to the amitriptyline group. Adverse events such as dry mouth and constipation were significantly lower in the tianeptine group than the amitriptyline group (P<0.05). CONCLUSIONS & INFERENCES Tianeptine is not inferior to amitriptyline for treating IBS-D in terms of both efficacy and tolerability.
Collapse
|
42
|
Ko BR, Won E, Adachi I, Aihara H, Asner DM, Aulchenko V, Aushev T, Aziz T, Bakich AM, Belous K, Bhardwaj V, Bhuyan B, Bischofberger M, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Chang MC, Chen A, Chen P, Cheon BG, Chilikin K, Cho IS, Cho K, Choi Y, Doležal Z, Drásal Z, Eidelman S, Fast JE, Gaur V, Gabyshev N, Garmash A, Goh YM, Golob B, Haba J, Hayasaka K, Hayashii H, Horii Y, Hoshi Y, Hou WS, Hsiung YB, Hyun HJ, Iijima T, Ishikawa A, Itoh R, Iwabuchi M, Iwasaki Y, Iwashita T, Julius T, Kang JH, Kawasaki T, Kiesling C, Kim HO, Kim JB, Kim KT, Kim MJ, Kim YJ, Kinoshita K, Koblitz S, Kodyš P, Korpar S, Križan P, Krokovny P, Kuhr T, Kuzmin A, Kwon YJ, Lange JS, Lee SH, Li J, Li Y, Libby J, Lim CL, Liu C, Liu Y, Liu ZQ, Liventsev D, Louvot R, Matvienko D, Miyazaki Y, Mizuk R, Mohanty GB, Moll A, Mori T, Muramatsu N, Nagasaka Y, Nakano E, Nakao M, Nakazawa H, Natkaniec Z, Nishida S, Nishimura K, Nitoh O, Ogawa S, Ohshima T, Okuno S, Olsen SL, Onuki Y, Ostrowicz W, Pakhlov P, Pakhlova G, Park CW, Park HK, Park KS, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Poluektov A, Ritter M, Röhrken M, Ryu S, Sahoo H, Sakai K, Sakai Y, Sanuki T, Sato Y, Schneider O, Schwanda C, Schwartz AJ, Seidl R, Senyo K, Sevior ME, Shapkin M, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Sibidanov A, Simon F, Smerkol P, Sohn YS, Sokolov A, Solovieva E, Stanič S, Starič M, Sumiyoshi T, Tanaka S, Tatishvili G, Teramoto Y, Trabelsi K, Tsuboyama T, Uchida M, Uehara S, Unno Y, Uno S, Varner G, Varvell KE, Vinokurova A, Vorobyev V, Wang CH, Wang P, Wang XL, Watanabe M, Watanabe Y, Yamamoto H, Yamashita Y, Yuan CZ, Zhang CC, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. Evidence for CP violation in the decay D+ → K(S)(0)π+. PHYSICAL REVIEW LETTERS 2012; 109:021601. [PMID: 23030153 DOI: 10.1103/physrevlett.109.021601] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2012] [Indexed: 06/01/2023]
Abstract
We observe evidence for CP violation in the decay D+ → K(S)(0)π+ using a data sample with an integrated luminosity of 977 fb(-1) collected by the Belle detector at the KEKB e+ e- asymmetric-energy collider. The CP asymmetry in the decay is measured to be (-0.363±0.094±0.067)%, which is 3.2 standard deviations away from zero, and is consistent with the expected CP violation due to the neutral kaon in the final state.
Collapse
|
43
|
Chang MH, Kim HS, Shin JH, Park KS. Facial identification in very low-resolution images simulating prosthetic vision. J Neural Eng 2012; 9:046012. [PMID: 22766585 DOI: 10.1088/1741-2560/9/4/046012] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
44
|
Sim SY, Jeon HS, Chung GS, Kim SK, Kwon SJ, Lee WK, Park KS. Fall detection algorithm for the elderly using acceleration sensors on the shoes. ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE 2012; 2011:4935-8. [PMID: 22255445 DOI: 10.1109/iembs.2011.6091223] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The rate of increase in the number of aging population in Korea is very rapid among OECD-member countries. And fall accident is one of the most common factors that threaten the health of the elderly. Therefore, it is needed to develop a fall detection system for the elderly. Most fall detection systems use accelerometers attached on the torso. And in various studies, it was verified that these systems have high sensitivity and high specificity. However, the elderly would feel uncomfortable when banding a sensor on the chest every day. Therefore, in this study, we attached an accelerometer on the shoes to detect fall in the elderly. This prototype system would be improved as a smaller, low-power system in the next study. Also, applying energy harvesting device to this shoe system is being developed to reduce the weight of battery.
Collapse
|
45
|
Ahn JK, Chebotaryov S, Choi JH, Choi S, Choi W, Choi Y, Jang HI, Jang JS, Jeon EJ, Jeong IS, Joo KK, Kim BR, Kim BC, Kim HS, Kim JY, Kim SB, Kim SH, Kim SY, Kim W, Kim YD, Lee J, Lee JK, Lim IT, Ma KJ, Pac MY, Park IG, Park JS, Park KS, Shin JW, Siyeon K, Yang BS, Yeo IS, Yi SH, Yu I. Observation of reactor electron antineutrinos disappearance in the RENO experiment. PHYSICAL REVIEW LETTERS 2012; 108:191802. [PMID: 23003027 DOI: 10.1103/physrevlett.108.191802] [Citation(s) in RCA: 105] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/02/2012] [Indexed: 06/01/2023]
Abstract
The RENO experiment has observed the disappearance of reactor electron antineutrinos, consistent with neutrino oscillations, with a significance of 4.9 standard deviations. Antineutrinos from six 2.8 GW(th) reactors at the Yonggwang Nuclear Power Plant in Korea, are detected by two identical detectors located at 294 and 1383 m, respectively, from the reactor array center. In the 229 d data-taking period between 11 August 2011 and 26 March 2012, the far (near) detector observed 17102 (154088) electron antineutrino candidate events with a background fraction of 5.5% (2.7%). The ratio of observed to expected numbers of antineutrinos in the far detector is 0.920±0.009(stat)±0.014(syst). From this deficit, we determine sin(2)2θ(13)=0.113±0.013(stat)±0.019(syst) based on a rate-only analysis.
Collapse
|
46
|
Li J, Adachi I, Aihara H, Arinstein K, Asner DM, Aulchenko V, Aushev T, Bakich AM, Bhardwaj V, Bhuyan B, Bischofberger M, Bondar A, Bozek A, Bračko M, Brovchenko O, Browder TE, Chang MC, Chen A, Chen P, Cheon BG, Chistov R, Cho K, Choi SK, Choi Y, Dalseno J, Doležal Z, Drutskoy A, Eidelman S, Esen S, Fast JE, Gaur V, Garmash A, Goh YM, Haba J, Hara T, Hayasaka K, Hayashii H, Horii Y, Hoshi Y, Hou WS, Hsiung YB, Hyun HJ, Iijima T, Inami K, Ishikawa A, Itoh R, Iwabuchi M, Iwasaki Y, Iwashita T, Julius T, Kang JH, Kapusta P, Katayama N, Kawasaki T, Kim HJ, Kim HO, Kim JB, Kim KT, Kim MJ, Kim YJ, Kinoshita K, Ko BR, Kobayashi N, Kodyš P, Korpar S, Križan P, Krokovny P, Kuhr T, Kumar R, Kuzmin A, Kwon YJ, Lange JS, Lee MJ, Lee SH, Li Y, Libby J, Liu C, Liu Y, Liu ZQ, Liventsev D, Louvot R, Matvienko D, McOnie S, Miyazaki Y, Mizuk R, Mohanty GB, Moll A, Mori T, Muramatsu N, Nakamura I, Nakano E, Nakao M, Nakazawa H, Natkaniec Z, Nishida S, Nishimura K, Nitoh O, Ogawa S, Ohshima T, Okuno S, Olsen SL, Ostrowicz W, Pakhlova G, Park CW, Park HK, Park KS, Pedlar TK, Peng T, Pestotnik R, Petrič M, Piilonen LE, Prim M, Röhrken M, Ryu S, Sahoo H, Sakai K, Sakai Y, Sanuki T, Sato Y, Schneider O, Schwanda C, Schwartz AJ, Senyo K, Seon O, Sevior ME, Shapkin M, Shebalin V, Shen CP, Shibata TA, Shiu JG, Simon F, Smerkol P, Sohn YS, Sokolov A, Stanič S, Starič M, Sumihama M, Sumiyoshi T, Tanaka S, Tatishvili G, Teramoto Y, Trabelsi K, Uchida M, Uehara S, Unno Y, Uno S, Urquijo P, Usov Y, Varner G, Varvell KE, Vorobyev V, Vossen A, Wang CH, Wang P, Watanabe M, Watanabe Y, Wicht J, Williams KM, Won E, Yamashita Y, Yuan CZ, Zhang ZP, Zhilich V, Zupanc A. First observation of B(s)(0) → J/ψη and B(s)(0) → J/ψη'. PHYSICAL REVIEW LETTERS 2012; 108:181808. [PMID: 22681063 DOI: 10.1103/physrevlett.108.181808] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Indexed: 06/01/2023]
Abstract
We report first observations of B(s)(0) → J/ψη and B(s)(0) → J/ψη'. The results are obtained from 121.4 fb(-1) of data collected at the Υ(5S) resonance with the Belle detector at the KEKB e+ e- collider. We obtain the branching fractions B(B(s)(0) → J/ψη)=[5.10±0.50(stat)±0.25(syst)(-0.79)(+1.14)(N(B(s)(*) B(s)(*))]×10(-4), and B(B(s)(0) → J/ψη')=[3.71±0.61(stat)±0.18(syst)(-0.57)(+0.83)(N(B(s)(*) B(s)(*))]×10(-4). The ratio of the two branching fractions is measured to be (B(B(s) → J/ψη'))/(B(B(s) → J/ψη))=0.73±0.14(stat)±0.02(syst).
Collapse
|
47
|
Adachi I, Aihara H, Asner DM, Aulchenko V, Aushev T, Aziz T, Bakich AM, Bay A, Bhardwaj V, Bhuyan B, Bischofberger M, Bondar A, Bozek A, Bračko M, Browder TE, Chen P, Cheon BG, Chilikin K, Chistov R, Cho K, Choi SK, Choi Y, Dalseno J, Danilov M, Doležal Z, Drásal Z, Eidelman S, Epifanov D, Fast JE, Gaur V, Gabyshev N, Garmash A, Goh YM, Golob B, Haba J, Hara K, Hara T, Hayasaka K, Hayashii H, Higuchi T, Horii Y, Hoshi Y, Hou WS, Hsiung YB, Hyun HJ, Iijima T, Ishikawa A, Itoh R, Iwabuchi M, Iwasaki Y, Iwashita T, Julius T, Kapusta P, Katayama N, Kawasaki T, Kichimi H, Kiesling C, Kim HJ, Kim HO, Kim JB, Kim JH, Kim KT, Kim YJ, Kinoshita K, Ko BR, Koblitz S, Kodyš P, Korpar S, Križan P, Krokovny P, Kuhr T, Kumar R, Kumita T, Kuzmin A, Kwon YJ, Lange JS, Lee SH, Li J, Li Y, Liu C, Liu Y, Liu ZQ, Liventsev D, Louvot R, Matvienko D, McOnie S, Miyabayashi K, Miyata H, Miyazaki Y, Mizuk R, Mohanty GB, Mori T, Muramatsu N, Nakano E, Nakao M, Nakazawa H, Neubauer S, Nishida S, Nishimura K, Nitoh O, Ogawa S, Ohshima T, Okuno S, Olsen SL, Onuki Y, Ozaki H, Pakhlov P, Pakhlova G, Park HK, Park KS, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Poluektov A, Röhrken M, Rozanska M, Sahoo H, Sakai K, Sakai Y, Sanuki T, Sato Y, Schneider O, Schwanda C, Schwartz AJ, Senyo K, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Sibidanov A, Simon F, Singh JB, Smerkol P, Sohn YS, Sokolov A, Solovieva E, Stanič S, Starič M, Sumihama M, Sumisawa K, Sumiyoshi T, Tanaka S, Tatishvili G, Teramoto Y, Tikhomirov I, Trabelsi K, Tsuboyama T, Uchida M, Uehara S, Uglov T, Unno Y, Uno S, Ushiroda Y, Vahsen SE, Varner G, Varvell KE, Vinokurova A, Vorobyev V, Wang CH, Wang MZ, Wang P, Watanabe M, Watanabe Y, Williams KM, Won E, Yabsley BD, Yamamoto H, Yamashita Y, Yamauchi M, Yusa Y, Zhang ZP, Zhilich V, Zupanc A, Zyukova O. Precise measurement of the CP violation parameter sin2φ1 in B0→(cc¯)K0 decays. PHYSICAL REVIEW LETTERS 2012; 108:171802. [PMID: 22680852 DOI: 10.1103/physrevlett.108.171802] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Indexed: 06/01/2023]
Abstract
We present a precise measurement of the CP violation parameter sin2φ1 and the direct CP violation parameter A(f) using the final data sample of 772×10(6) BB[over ¯] pairs collected at the Υ(4S) resonance with the Belle detector at the KEKB asymmetric-energy e(+)e(-) collider. One neutral B meson is reconstructed in a J/ψK(S)(0), ψ(2S)K(S)(0), χ(c1)K(S)(0), or J/ψK(L)(0) CP eigenstate and its flavor is identified from the decay products of the accompanying B meson. From the distribution of proper-time intervals between the two B decays, we obtain the following CP violation parameters: sin2φ1=0.667±0.023(stat)±0.012(syst) and A(f)=0.006±0.016(stat)±0.012(syst).
Collapse
|
48
|
Seo HJ, Kim YJ, Cho KB, Kim ES, Hwang IS, Baek SK, Park KS. Nodal metastasis after successful endoscopic submucosal dissection for colorectal mucosal cancer. Endoscopy 2012; 43 Suppl 2 UCTN:E374-5. [PMID: 22068653 DOI: 10.1055/s-0030-1256705] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
|
49
|
Starič M, Aihara H, Arinstein K, Asner DM, Aushev T, Bakich AM, Bay A, Bhardwaj V, Bhuyan B, Bozek A, Bračko M, Browder TE, Chen A, Chen P, Cheon BG, Chilikin K, Chistov R, Cho IS, Cho K, Choi Y, Doležal Z, Drásal Z, Eidelman S, Fast JE, Gaur V, Gabyshev N, Golob B, Haba J, Hayasaka K, Horii Y, Hoshi Y, Hou WS, Hsiung YB, Iijima T, Inami K, Ishikawa A, Itoh R, Iwabuchi M, Iwasaki Y, Iwashita T, Julius T, Kang JH, Kawasaki T, Kiesling C, Kim HJ, Kim HO, Kim JB, Kim KT, Kim MJ, Kim YJ, Kinoshita K, Ko BR, Kobayashi N, Koblitz S, Kodyš P, Korpar S, Križan P, Kumita T, Kwon YJ, Lange JS, Lee SH, Li J, Li Y, Libby J, Liu C, Liu ZQ, Louvot R, McOnie S, Miyabayashi K, Miyata H, Miyazaki Y, Mohanty GB, Nakano E, Natkaniec Z, Nishida S, Nitoh O, Nozaki T, Ohshima T, Okuno S, Olsen SL, Pakhlova G, Park HK, Park KS, Pestotnik R, Petrič M, Piilonen LE, Röhrken M, Ryu S, Sahoo H, Sakai K, Sakai Y, Sanuki T, Schneider O, Schwanda C, Schwartz AJ, Seon O, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Simon F, Smerkol P, Sohn YS, Sokolov A, Stanič S, Sumihama M, Sumisawa K, Tatishvili G, Teramoto Y, Trabelsi K, Uchida M, Uehara S, Uglov T, Unno Y, Uno S, Urquijo P, Varner G, Vossen A, Wang CH, Wang MZ, Watanabe M, Watanabe Y, Williams KM, Won E, Yabsley BD, Yamashita Y, Yuan CZ, Zhang CC, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. Search for CP violation in D± meson decays to ϕπ±. PHYSICAL REVIEW LETTERS 2012; 108:071801. [PMID: 22401192 DOI: 10.1103/physrevlett.108.071801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2011] [Indexed: 05/31/2023]
Abstract
We search for CP violation in Cabibbo-suppressed charged D meson decays by measuring the difference between the CP-violating asymmetries for the Cabibbo-suppressed decays D(±)→K(+)K(-)π(±) and the Cabibbo-favored decays D(s)(±)→K(+)K(-)π(±) in the K(+)K(-) mass region of the ϕ resonance. Using 955 fb(-1) of data collected with the Belle detector, we obtain A(CP)(D+→ϕπ+)=(+0.51±0.28±0.05)%. The measurement improves the sensitivity of previous searches by more than a factor of 5. We find no evidence for direct CP violation.
Collapse
|
50
|
Kim ES, Park KS, Cho KB, Kim MJ. Adenocarcinoma occurring at the interposed colon graft for treatment of benign esophageal stricture. Dis Esophagus 2012; 25:175. [PMID: 20459445 DOI: 10.1111/j.1442-2050.2010.01056.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|